+

WO2004041190A3 - Composition for the treatment of macular degenration - Google Patents

Composition for the treatment of macular degenration Download PDF

Info

Publication number
WO2004041190A3
WO2004041190A3 PCT/US2003/034661 US0334661W WO2004041190A3 WO 2004041190 A3 WO2004041190 A3 WO 2004041190A3 US 0334661 W US0334661 W US 0334661W WO 2004041190 A3 WO2004041190 A3 WO 2004041190A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
composition
disclosed
methods
degenration
Prior art date
Application number
PCT/US2003/034661
Other languages
French (fr)
Other versions
WO2004041190A2 (en
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Jerome B Zeldis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Jerome B Zeldis filed Critical Celgene Corp
Priority to EP03781615A priority Critical patent/EP1562597A4/en
Priority to AU2003287381A priority patent/AU2003287381B2/en
Priority to JP2004550329A priority patent/JP2006508950A/en
Priority to MXPA05004488A priority patent/MXPA05004488A/en
Priority to BR0315931-0A priority patent/BR0315931A/en
Priority to NZ540186A priority patent/NZ540186A/en
Priority to CA002504024A priority patent/CA2504024A1/en
Publication of WO2004041190A2 publication Critical patent/WO2004041190A2/en
Publication of WO2004041190A3 publication Critical patent/WO2004041190A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
PCT/US2003/034661 2002-10-31 2003-10-31 Composition for the treatment of macular degenration WO2004041190A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03781615A EP1562597A4 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
AU2003287381A AU2003287381B2 (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degenration
JP2004550329A JP2006508950A (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degeneration
MXPA05004488A MXPA05004488A (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degenration.
BR0315931-0A BR0315931A (en) 2002-10-31 2003-10-31 Method of treating, preventing or controlling macular degeneration and pharmaceutical composition
NZ540186A NZ540186A (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degeneration
CA002504024A CA2504024A1 (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42289902P 2002-10-31 2002-10-31
US60/422,899 2002-10-31

Publications (2)

Publication Number Publication Date
WO2004041190A2 WO2004041190A2 (en) 2004-05-21
WO2004041190A3 true WO2004041190A3 (en) 2004-09-02

Family

ID=32312566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034661 WO2004041190A2 (en) 2002-10-31 2003-10-31 Composition for the treatment of macular degenration

Country Status (12)

Country Link
EP (1) EP1562597A4 (en)
JP (1) JP2006508950A (en)
KR (1) KR20050061586A (en)
CN (1) CN1732001A (en)
AU (1) AU2003287381B2 (en)
BR (1) BR0315931A (en)
CA (1) CA2504024A1 (en)
MX (1) MXPA05004488A (en)
NZ (1) NZ540186A (en)
TW (1) TWI310312B (en)
WO (1) WO2004041190A2 (en)
ZA (1) ZA200503467B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CN101696205B (en) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
US9643950B2 (en) 2012-10-22 2017-05-09 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20180126273A1 (en) * 2016-11-09 2018-05-10 Agape Assets, LLC Systems and methods for promoting medication adherence

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517A (en) * 1996-07-24 1997-06-03 Celgene Corporation Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1274549B (en) * 1995-05-23 1997-07-17 Indena Spa USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP0925294B3 (en) * 1996-07-24 2018-07-04 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
EP1361210B1 (en) * 1996-08-12 2008-12-24 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
PT1920773E (en) * 1996-11-05 2011-01-27 Childrens Medical Center Thalidomide and dexamethasone for the treatment of tumors
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
JP2002520287A (en) * 1998-07-10 2002-07-09 ザ・ユニバーシティ・オブ・シドニー Prophylactic treatment of angiogenesis in macular degeneration
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
JP2000159761A (en) * 1998-11-30 2000-06-13 Yoshio Takeuchi Fluorothalidomide
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7812169B2 (en) * 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
SK9782003A3 (en) * 2001-02-02 2004-01-08 Schering Corp 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
CA2457319C (en) * 2001-08-06 2011-07-05 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
AU2003272471B2 (en) * 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517A (en) * 1996-07-24 1997-06-03 Celgene Corporation Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1562597A4 *

Also Published As

Publication number Publication date
WO2004041190A2 (en) 2004-05-21
NZ540186A (en) 2008-03-28
MXPA05004488A (en) 2005-07-26
JP2006508950A (en) 2006-03-16
EP1562597A4 (en) 2008-05-14
CN1732001A (en) 2006-02-08
ZA200503467B (en) 2006-08-30
BR0315931A (en) 2005-09-13
TW200423936A (en) 2004-11-16
KR20050061586A (en) 2005-06-22
EP1562597A2 (en) 2005-08-17
CA2504024A1 (en) 2004-05-21
AU2003287381A1 (en) 2004-06-07
AU2003287381B2 (en) 2008-03-06
TWI310312B (en) 2009-06-01

Similar Documents

Publication Publication Date Title
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
BRPI0315315B8 (en)
BRPI0415971A (en) method for treating, preventing or controlling macular degeneration, and pharmaceutical composition
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
IL178591A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for the treatment and management of myelodysplastic syndromes
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
HK1080390A1 (en) Pharmaceutical composition for thrombin peptide derivatives
WO2004006859A3 (en) Platinum compound
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
WO2004041190A3 (en) Composition for the treatment of macular degenration
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
WO2006063164A3 (en) Compositions and methods for treating neuroendocrine tumors
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
WO2005110085A3 (en) Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
MX2010005009A (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction.
BRPI0415970A (en) method for treating, preventing or controlling macular degeneration, and pharmaceutical composition
WO2004028463A3 (en) Methods and compositions for the treatment of lupus using clofarabine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004488

Country of ref document: MX

Ref document number: 2504024

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004550329

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005/03467

Country of ref document: ZA

Ref document number: 200503467

Country of ref document: ZA

Ref document number: 1020057007531

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 168312

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003287381

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 540186

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 540186

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003781615

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057007531

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038A8093X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003781615

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0315931

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载